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“Old” molecules, such as enzymes,
inhibitors, and related proteins, are being redis-
covered under the new light of proteomics
research. Proteomic biomarkers have become a
major focus,  especially in the area of cancer
research, because most of the functional infor-
mation of the cancer-associated genes resides in
the proteome. Because cancer is a complex dis-
ease, it might require a panel of multiple
biomarkers to achieve sufficient clinical efficacy.
Serum/plasma is the most accessible biological
specimen collected from patients. The develop-
ment of serum proteomic diagnostics could be
the most promising new test for cancer. 
Why a Single Biomarker is Not 
Sufficient as Cancer Diagnostics
The human proteome is an exceptionally
complex biological system involving proteins
with posttranslational modifications and
dynamic intermolecular collisions. These pro-
tein complexes can be regulated by signals
from cancer cells, their surrounding tissue
microenvironment, and/or from the host. Some
proteins are secreted and/or cleaved into the
extra-cellular space and may represent valuable
serum biomarkers for diagnostic purpose. It is
estimated that the cancer proteome may
include more than 1 million proteins as a result
of posttranslational modifications. Therefore,
finding the elusive single disease-related pro-
tein would require the laborious separation and
identification of every protein biomarker (1–3).
Until recently, the low molecular weight
range (<15 kDa) of the circulatory proteome
and metabolome went largely uncharacterized.
However, this collection of low molecular
weight molecules promises to contain a rich
source of previously undiscovered biomarkers
(4). This is because of biological processes that
give rise to cascades of biomarker fragments
from enzyme-generated proteolytic activity.
The rich information archive can arise within
the unique disease-tissue microenvironment.
These low molecular weight molecules exist
below the range of detection achieved by
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conventional two-dimensional gel electrophore-
sis, because they cannot be efficiently separated
by gel-based techniques. As a result, investiga-
tors have turned to mass spectroscopy, which
exhibits its optimal performance in the low
molecular weight range. Such complexity
clearly highlights the need for ultra-high 
resolution proteomic technology for robust
quantitative protein measurements and data
acquisition (5).
Finding New Cancer Biomarkers 
The search for new cancer biomarkers con-
sists of three steps: discovery, validation, and
translation. Discovery research to find candi-
date biomarkers is relatively easy. Many
potential biomarker candidates could be dis-
covered using powerful technologies, such as
protein microarrays and mass spectrometry.
However, validation of biomarkers with con-
sistent analytical performance and clinical sig-
nificance in a general population is difficult.
Furthermore, the translation of these biomark-
ers into clinical diagnostics with the perfor-
mance characteristics of a clinical assay is not
easy and labor intensive. It also requires hun-
dreds, if not thousands of samples to be ana-
lyzed and generates enormous amount of data
to be processed (6,7). 
The approach for cancer biomarker discov-
ery and validation in our laboratory starts
with the selection of the right technologies to
discover biomarkers. We use protein chips and
mass spectrometry. Then, we identify well-
characterized clinical specimens, followed by
the development of bioinformatics tools for
data analysis and multiplexing of biomarkers
because most diseases (e.g., cancer) are hetero-
geneous. The design of multicenter case con-
trol study with extensive clinical validation is
important to minimize the impact of possible
confounding variables. Finally, we believe that
proteomic profiling is not sufficient. The goal
is to identify biomarkers with biological and
clinical significances.
Prostate-Specific Antigen: New
Application for an “Old” Enzyme?
Prostate cancer is the leading cause of
cancer in the United States. The diagnosis of
prostate cancer is most often suspected after
finding an elevated serum prostate-specific
antigen (PSA) or abnormal findings on digital
rectal examination (DRE). 
PSA is a protease. It is a 27-kD glycoprotein
that is produced by the secretory cells that line
the prostate glands (acini). PSA is released
from the prostate epithelial cell as a pro-
enzyme (pPSA) with a 7-amino acid peptide
chain attached to it (8). As it is secreted into
the lumen, the propeptide is removed by
human kallikrein 2 to generate active and
mature form of PSA. This molecule then
undergoes proteolysis to generate inactive
PSA, which enters the bloodstream and circu-
lates in an unbound state (free PSA). A small
amount of active PSA diffuses into the circula-
tion and is rapidly bound by protease
inhibitors, including alpha-1-antichymotrypsin
(ACT) and alpha-2-macroglobulin (9). Serum
PSA that is measurable by current clinical
immunoassays was found to exist primarily as
either the free form (free PSA) or bound to ACT.
Free PSA in serum is now known to be
composed of at least three distinct molecular
forms of inactive PSA: pPSA, bPSA, and iPSA.
Of particular interest is the proenzyme, pPSA,
and its association with cancer. A second form
of PSA, termed benign PSA (bPSA) is an inter-
nally cleaved or degraded form of PSA that is
more highly associated with benign prostatic
hyperplasia (BPH) (10). Preliminary research
indicated that pPSA could improve the diag-
nostic utility of PSA (11).
Enzyme-Related Proteins 
as Biomarkers for Ovarian Cancer
Ovarian cancer is one of the most deadly
diseases. Early detection remains the most
promising approach to improve long-term
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survival of patients. In a recent multi-center
serum proteomics study, more than 500
patients with invasive epithelial ovarian
cancer, benign pelvic masses, and healthy con-
trols were included (12). Data from ovarian
cancer patients and healthy women at two
centers were analyzed independently and the
results cross-validated to discover potential
biomarkers. The results were validated using
the samples from two of the remaining cen-
ters. After protein identification, biomarkers
were tested on samples from the fifth center,
which included healthy women, women with
ovarian cancer, and patients with breast,
colon, and prostate cancers. Three biomarkers
were identified as follows: (1) apolipoprotein
A1 (downregulated in cancer); (2) a truncated
form of transthyretin (downregulated); and (3)
a cleavage fragment of inter-alpha-trypsin
inhibitor heavy chain H4 (ITIH4) (upregulated).
In the independent validation to detect early
stage invasive epithelial ovarian cancer from
healthy controls, the sensitivity of a multivari-
ate model combining the three biomarkers and
CA125 (74%) was higher than that of CA125
alone (65%) at a matched specificity of 97%.
When compared at a fixed sensitivity of 83%,
the specificity of the model (94%) was signifi-
cantly better than that of CA125 alone (52%).
These biomarkers demonstrated the potential
to improve the detection of early stage ovar-
ian cancer.
Among the three biomarkers, the cleaved
form of ITIH4 is the most interesting. Several
proteolytically derived fragments from the
proline-rich region (PRR) of human ITIH4
have been identified by surface-enhanced or
matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (SELDI-TOF-
MS or MALDI-TOF-MS) as potential disease
markers (13). The ITIH4-related fragments were
first immunocaptured by beads coupled with
peptide-specific antibodies. The eluates were
analyzed by SELDI-TOF-MS. In addition,
freshly collected and immediately processed
serum and plasma samples were used to ana-
lyze the ex vivo stability of these ITIH4 frag-
ments. Human serum ITIH4 was shown to be
extensively proteolytically processed within
the PRR, and its fragmentation patterns were
closely associated with different disease con-
ditions. Fragmentation patterns were gener-
ally consistent with cleavages by endoprotease
followed by exoprotease actions. Observed
fragments changed little under different assay
conditions or blood collection and processing
procedures. The fragmentation patterns within
the PRR of human serum ITIH4 are associated
with different disease conditions and may
hold important diagnostic information. 
Conclusion
The future of cancer diagnostics will be
based on a panel of proteomic biomarkers.
They could be used to detect cancer at an
early stage, to predict and to direct therapies.
Enzymes and related proteins are important
biological molecules, which could serve as
cancer biomarkers. These biomarkers could be
intact or fragments of proteins. The challenge
is to be able to find and validate these poten-
tial biomarkers as clinical diagnostics. With
the advances in proteomic technologies, we
are closer than ever to find these “new”
enzyme molecules or fragments. The transla-
tion of newly discovered biomarkers could
provide an opportunity to revolutionize the
era of personalized medicine.
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